KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Xenon Pharmaceuticals (XENE) Amortizatization of Intangibles (2018 - 2025)

Xenon Pharmaceuticals (XENE) has disclosed Amortizatization of Intangibles for 6 consecutive years, with $334000.0 as the latest value for Q4 2025.

  • On a quarterly basis, Amortizatization of Intangibles rose 4.7% to $334000.0 in Q4 2025 year-over-year; TTM through Dec 2025 was $1.3 million, a 4.7% increase, with the full-year FY2025 number at $1.3 million, up 4.7% from a year prior.
  • Amortizatization of Intangibles was $334000.0 for Q4 2025 at Xenon Pharmaceuticals, up from $330000.0 in the prior quarter.
  • In the past five years, Amortizatization of Intangibles ranged from a high of $334000.0 in Q4 2025 to a low of -$4.6 million in Q4 2023.
  • A 3-year average of -$229888.9 and a median of $319000.0 in 2024 define the central range for Amortizatization of Intangibles.
  • Peak YoY movement for Amortizatization of Intangibles: skyrocketed 106.88% in 2024, then increased 4.21% in 2025.
  • Xenon Pharmaceuticals' Amortizatization of Intangibles stood at -$4.6 million in 2023, then surged by 106.88% to $319000.0 in 2024, then increased by 4.7% to $334000.0 in 2025.
  • Per Business Quant, the three most recent readings for XENE's Amortizatization of Intangibles are $334000.0 (Q4 2025), $330000.0 (Q3 2025), and $327000.0 (Q2 2025).